EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
EPRS was delisted on the 3rd of August, 2016.
24 hedge funds and large institutions have $17.2M invested in EPIRUS BIOPHARMACEUTICALS INC COM in 2014 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 5 closing their positions.
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
14% more funds holding
Funds holding: 21 → 24 (+3)
19% less capital invested
Capital invested by funds: $21.3M → $17.2M (-$4.04M)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$392K |
| 2 |
Renaissance Technologies
New York
|
+$188K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$103K |
| 4 |
SIM
Spark Investment Management
New York
|
+$92K |
| 5 |
Goldman Sachs
New York
|
+$55.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$216K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$154K |
| 3 |
Jennison Associates
New York
|
-$89K |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$70.4K |
| 5 |
A
Abingworth
London,
United Kingdom
|
-$56K |
EPRS Hedge Fund Activity: Q4 2014 in Review
24 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) for Q4 2014, worth a combined $17.2M — down 19% from $21.3M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new EPRS positions and 5 closed out — a net gain of 4 holders — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $392K. The largest seller was D.E. Shaw & Co, exiting entirely with an estimated $216K sold.
- 24 institutional investors held EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) as of Q4 2014, up from 21 in Q3 2014.
- Funds reported $17.2M of EPIRUS BIOPHARMACEUTICALS INC COM stock for Q4 2014, down 19% quarter-over-quarter.
- 9 funds opened new EPIRUS BIOPHARMACEUTICALS INC COM positions in Q4 2014 and 5 closed out, a net change of +4 holders.
- The largest EPIRUS BIOPHARMACEUTICALS INC COM buyer in Q4 2014 was Cormorant Asset Management, an estimated $392K added.
- The largest EPIRUS BIOPHARMACEUTICALS INC COM seller in Q4 2014 was D.E. Shaw & Co, an estimated $216K sold.
Based on aggregated 13F filings for Q4 2014.